# US 2023/0065827 A1 · Immunomodulators

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0065827 A1
- Document ID: US20230065827A1
- Status: Published application
- Kind: A1
- Application number: 17/791,027
- Filed: 2020-11-19
- Published: 2023-03-02
- Earliest claimed: 2020-01-06
- Assignees: Bristol-Myers Squibb Company
- Applicants: Bristol-Myers Squibb Company
- Inventors: Tao WANG; Paul Michael SCOLA; Zhongxing ZHANG
- Web page: https://patentgrep.com/patent/US20230065827A1

## CPC

- A61K 38/12: Cyclic peptides {, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C (A61K38/043 - A61K38/046 take precedence)}
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/04: Immunostimulants
- C07K 7/56: the cyclisation not occurring through 2,4-diamino-butanoic acid
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

In accordance with the present disclosure, macrocyclic compounds have been discovered that bind to PD-L1 and are capable of inhibiting the interaction of PD-L1 with PD-1 and CD80. These macrocyclic compounds exhibit in vitro immunomodulatory efficacy thus making them therapeutic candidates for the treatment of various diseases including cancer and infectious diseases.

## Claims

### Claim 1

A compound of formula (I)
or a pharmaceutically acceptable salt thereof, wherein:
Rx and Ry are independently H,
provided that at least one of Rx and Ry is other than H;
R1 is H, halogen or C1-C6 alkyl;
R2 and R3 are independently H, halogen, C1-C6 alkyl, or aryl; said aryl group substituted with 0-3 R3a;
R3a is halogen or COOR4;
R4 is H or C1-C6 alkyl; and
R9 is H or C1-C3 alkyl.

### Claim 2 (depends on 1)

The compound of claim 1 wherein
R2 and R3 are independently H, halogen, C1-C6 alkyl or phenyl; said phenyl group substituted with 0-3 R3a;
R3a is halogen or COOR4;
R4 is H or C1-C6 alkyl; and
R9 is H or C1-C3 alkyl.

### Claim 3 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein Rx is H.

### Claim 4 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein Ry is H.

### Claim 5 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R9 is H or —CH3.

### Claim 6 (depends on 1, 2, 3, 4, 5)

A pharmaceutical composition comprising a compound of any of claims 1 to 5, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

### Claim 7 (depends on 1, 2, 3, 4, 5)

A method of enhancing, stimulating, and/or increasing an immune response in a subject in need thereof, said method comprising administering to the subject a therapeutically effective amount of a compound of any one of claims 1 to 5, or a therapeutically acceptable salt thereof.

### Claim 8 (depends on 1, 2, 3, 4, 5)

A method of inhibiting growth, proliferation, or metastasis of cancer cells in a subject in need thereof, said method comprising administering to the subject a therapeutically effective amount of a compound of any one of claims 1 to 5, or a therapeutically acceptable salt thereof.

### Claim 9 (depends on 8)

The method of claim 8, wherein the cancer is selected from melanoma, renal cell carcinoma, squamous non-small cell lung cancer (NSCLC), non-squamous NSCLC, colorectal cancer, castration-resistant prostate cancer, ovarian cancer, gastric cancer, hepatocellular carcinoma, pancreatic carcinoma, squamous cell carcinoma of the head and neck, carcinomas of the esophagus, gastrointestinal tract and breast, and hematological malignancies.

### Claim 10 (depends on 1, 2, 3, 4, 5)

A method of treating an infectious disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of any one of claims 1 to 5, or a therapeutically acceptable salt thereof.

### Claim 11 (depends on 10)

The method of claim 10, wherein the infectious disease is caused by a virus.

### Claim 12 (depends on 1, 2, 3, 4, 5)

A method of treating septic shock in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of any one of claims 1 to 5, or a therapeutically acceptable salt thereof.

### Claim 13 (depends on 1, 2, 3, 4, 5)

A method for blocking the interaction of PD-L1 with PD-1 and/or CD80 in a subject, said method comprising administering to the subject a therapeutically effective amount of a compound of any one of claims 1 to 5, or a therapeutically acceptable salt thereof.
